Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism

Journal of Sexual Medicine

Volumn 6, Issue 9, 2009, Pages 2494-2504

  Bivalacqua, Trinity J ^a   Musicki, Biljana ^a   Hsu, Lewis L ^b,c   Gladwin, Mark T ^d   Burnett, Arthur L ^a   Champion, Hunter C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cavolae; Endothelium; Erectile Dysfunction; Fibrosis; Ischemic Priapism; Nitric Oxide

Indexed keywords

COLLAGEN; HYDROXYPROLINE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DISEASE ASSOCIATION; ENDOTHELIUM; IN VIVO STUDY; MALE; MORPHOMETRICS; MOUSE; NERVE STIMULATION; NONHUMAN; PATHOPHYSIOLOGY; PENIS; PHENOTYPE; PRIAPISM; PRIORITY JOURNAL; PROTEIN CONTENT; SICKLE CELL ANEMIA; SMOOTH MUSCLE FIBER; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY; ANALYSIS OF VARIANCE; ANIMAL; COMPLICATION; DISEASE MODEL; FEMALE; FIBROSIS; ISCHEMIA; PENIS ERECTION; VASCULAR ENDOTHELIUM;

ANALYSIS OF VARIANCE; ANEMIA, SICKLE CELL; ANIMALS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; FIBROSIS; ISCHEMIA; MALE; MICE; MICE, TRANSGENIC; NITRIC OXIDE; PENILE ERECTION; PENIS; PRIAPISM;

EID: 69949085119     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01359.x     Document Type: Article

References (37)

1. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID, Members of the Erectile Dysfunction Guideline Update Panel, Americal Urological Association. American Urological Association Guideline on the management of priapism. J Urol 2003;170:1318-24.
2. Bivalacqua TJ, Burnett AL. Priapism: New concepts in the pathophysiology and new treatment strategies. Curr Urol Rep 2006;7:497-502.
3. Chinegwundoh F, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev 2004;4:CD004198.
4. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA 2005;102:1661-6.
5. Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL. Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol 2007;51:1732-40.
6. Evliyaoglu Y, Kayrin L, Kaya B. Effect of pentoxifylline on veno-occlusive priapism-induced corporeal tissue lipid peroxidation in a rat model. Urol Res 1997;25:143-7.
7. Munarriz R, Park K, Huang YH, Saenz de Tejada I, Moreland RB, Goldstein I, Traish AM. Reperfusion of ishcemic corporal tissue: Physiologic and biochemical changes in an animal model of ischemic priapism. Urology 2003;62:760-4.
8. Ul-Hasan M, El-Sakka AI, Lee C, Yen TS, Dahiya R, Lue TF. Expression of TGF-beta-1 mRNA and ultrastructural alterations in pharmacologically induced prolonged penile erection in a canine model. J Urol 1998;160:2263-6.
9. Mi T, Abbasi S, Zhang H, Uray K, Chunn JL, Xia LW, Molina JG, Weisbrodt NW, Kellems RE, Blackburn MR, Xia Y. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 2008;118:1491-501.
10. Adeyoju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, Akenova A, Akinyanju O, Cinkotai K, O'Reilly PH. Priapism in sickle cell disease; incidence, risk factors and complications - An international multicentre study. BJU Int 2002;90:898-902.
11. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med 1980;140:1434-7.
12. Nelson JH, Winter CC. Priapism: Evolution of management in 48 patients in a 22-year series. J Urol 1977;117:455-8.
13. Beuzard Y. Transgenic mouse models of sickle cell disease. Curr Opin Hematol 1996;3:150-5.
14. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007;109:3088-98.
15. Pászty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, Rubin EM. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997;278:876-8.
16. Bivalacqua TJ, Diner EK, Novak TE, Vohra Y, Sikka SC, Champion HC, Kadowitz PJ, Hellstrom WJ. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol 2000;163:1992-8.
17. Tokuyasu KT. A technique for ultracryotomy of cell susupensions and tissues. J Cell Biol 1973;57:551-65.
18. Peterson TE, Poppa V, Ueba H, Wu A, Yan C, Berk BC. Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ Res 1999;85:29-37.
19. Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol 2008;294:L24-33.
20. Bivalacqua TJ, Burnett AL, Hellstrom WJ, Champion HC. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: Influence of in vivo gene therapy of anti-arginase. Am J Physiol Heart Circ Physiol 2007;292:H1340-51.
21. Spycher MA, Hauri D. The ultrastructure of the erectile tissue in priapism. J Urol 1986;135:142-7.
22. Broderick GA, Gordon D, Hypolite J, Levin RM. Anoxia and corporal smooth muscle dysfunction: Mechanism for ischemic priapism. J Urol 1994;151:259-62.
23. Eland IA, Van Der Lei J, Stricker BHC, Sturkenboom MJCM. Incidence of priapism in the general population. Urology 2001;57:970-2.
24. Earle CM, Stuckey BGA, Ching HL, Wisniewski ZS. The incidence and management of priapism in western Australia: A 16 year audit. Int J Impot Res 2003;15:272-6.
25. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med 1980;140:1434-7.
26. Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med 2008;5:1244-50.
27. Linder AE, Leite R, Lauria K, Mills TM, Webb RC. Penile erection requires association of soluble guanylyl cyclase with endothelial caveolin-1 in rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol 2006;290:R1302-8.
28. Bakircioglu ME, Sievert KD, Nunes L, Lau A, Lin CS, Lue TF. Decreased trabecular smooth muscle and caveolin-1 expression in the penile tissue of aged rats. J Urol 2001;166:734-8.
29. Peterson TE, Poppa V, Ueba H, Wu A, Yan C, Berk BC. Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ Res 1999;85:29-37.
30. Darblade B, Caillaud D, Poirot M, Fouque M, Thiers JC, Rami J, Bayard F, Arnal JF. Alteration of plasmalemmal caveolae mimics endothelial dysfunction observed in atheromatous rabbit aorta. Cardiovasc Res 2001;50:566-76.
31. Manci EA, Hillery CA, Bodian CA, Zhang ZG, Lutty GA, Coller BS. Pathology of Berkeley sickle cell mice: Similarities and differences with human sickle cell disease. Blood 2006;107:1651-8.
32. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006;3:1077-84.
33. Burnett AL, Bivalacqua TJ. Glucose-6-phosphate dehydrogenase deficiency: An etiology for idiopathic priapism? J Sex Med 2008;5:237-40.
34. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology 2006;67:1043-8.
35. Jin YC, Gam SC, Jung JH, Hyun JS, Chang KC, Hyun JS. Expression and activity of heme oxygenase-1 in artificially induced low-flow priapism in rat penile tissues. J Sex Med 2008;5:1876-82.
36. Kato GJ, Gladwin MT. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 2008;300:2638-46.
37. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radic Biol Med 2008;44:1506-28.